Table 1.
Characteristics of the patients
| Baduanjin exercise group (n = 43) | Routine care group (n = 44) | p | |
|---|---|---|---|
| Gender, n | |||
| Male | 26 | 30 | 0.507 |
| Female | 17 | 14 | |
| Age, years | 55.60±11.23 | 54.63±11.88 | 0.643 |
| Education, n | 0.638 | ||
| Junior high school | 10 | 8 | |
| Senior high school and middle special school | 23 | 22 | |
| Junior college, college graduate, and above | 10 | 14 | |
| Marital status, n | 0.866 | ||
| Life with spouse | 31 | 31 | |
| Unmarried, widowed, or divorced | 12 | 13 | |
| Stage, n | 0.721 | ||
| I | 10 | 13 | |
| II | 29 | 26 | |
| III | 4 | 5 | |
| Monthly family income, n | |||
| RMB <2,000 | 5 | 3 | 0.740 |
| RMB 2,000–5,000 | 11 | 12 | |
| RMB >5,000 | 27 | 29 | |
| Operation, n | |||
| Radical resection of rectal cancer | 25 | 28 | 0.663 |
| Radical operation of colon cancer | 18 | 16 | |
| Chemotherapy protocol, n | |||
| XELOX | 8 | 11 | 0.645 |
| FOLFOX | 22 | 23 | |
| FOLFIRI | 13 | 10 | |
| BFI score | 4.37±2.24 | 4.70±2.45 | 0.510 |
| KPS score | 76.51±11.31 | 74.77±14.06 | 0.527 |
| PSQI score | 10.51±1.45 | 10.45±2.13 | 0.884 |
XELOX, capecitabine and oxaliplatin; FOLFOX, folinic acid, 5-fluorouracil, and oxaliplatin; FOLFIRI, folinic acid, 5-fluorouracil, and irinotecan; BFI, Brief Fatigue Inventory; KPS, Karnofsky Performance Status; PSQI, Pittsburgh Sleep Quality Index.